


Amarapurkar DN. Asia pacific epidemiology of non alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 22 (2007); 788-793.


Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, Cavallo MG. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011 Jul 12; 9(1):85.

Barrows B, Parks E. Contributions of different fatty acid sources to very low-density lipoprotein triacylglycerol in the fasted and fed states. J Clin Endocrinol Metab. 2006; 91:1446-52.


Chen CH, Huang MH, Yang JC. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of


Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, et al. The clinicopathological profile of Indian patients with nonalcoholic fatty liver
Disease (NAFLD) is different from that in the West. Dig Dis Sci. 2007; 52: 2368-74.


- Duseja A, Das A, Das R. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci. 2007; 52:2368–74.


Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids in Health and Disease. April 2010; 9:42.


Luxmi S, Sattar RA, Ara J; Association of non alcoholic fatty liver with type 2 diabetes mellitus. JLUMHS. 2008; 188 -193.


Merat S. Prevalence of fatty liver disease amount type 2 diabetes mellitus patients and its Relation to insulin resistance. Middle East Journal of Digestive Diseases. 2009; Vol .1 No. 2.


Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology. 2005; 41: 204-206.


- Orellana M, Rodrigo R, Varela N, Araya J, Poniachik J, Csendes A, Smok G, Videla L. Relationship between in vivo chlorzoxazone hydroxylation, hepatic
cytochrome P450 2E1 content and liver injury in obese non-alcoholic fatty liver disease patients. Hepatol Res. 2006; 34:57-63.


Setji T, Holland N, Sanders L, Pereira K, Diehl A, Brown A. Non-alcoholic steatohepatitis and non-alcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006; 91:1741–1747.


Speliotes EK, Yerges-Armstrong LM, Wu J. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011; 7:e1001324.


Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin like phospholipase domain containing 3 gene (PNPLA3) on the


➢ Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabetes Med. 2007; 24:1-6.


Tilg H, Hotamisligil GS. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology. 2006; 131: 934-945.


- Yoneda M, Mawatari H, Fujita K, et al. Highsensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007; 42(7):573-782.


